Literature DB >> 15806297

Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression.

Ayguen Sahin1, Markus Velten, Torsten Pietsch, Pascal Knuefermann, Ali Fuat Okuducu, Jens Claus Hahne, Nicolas Wernert.   

Abstract

Malignant gliomas represent the most aggressive tumours of the central nervous system and are characterised by both extensive proliferation and invasive growth. Matrix degrading proteases called matrix metalloproteinases (MMPs), particularly MMP-9, play a crucial role in glioma infiltration. The activity of these enzymes is regulated at different levels. In this regard, the control of transcriptional activity by specific transcription factors is believed to be very important. In the present study, we examined whether rat C6 glioma cells express the Ets 1 transcription factor and whether inhibition of Ets 1 by a specific decoy strategy affects C6 glioma cell proliferation and mmp-9 expression. We found that C6 glioma cells express Ets 1 and can efficiently be transfected with an Ets 1-specific decoy oligodesoxynucleotide (ODN). This ODN significantly reduces cell proliferation and mmp-9 expression, the latter in a dose-dependent manner. We conclude that inhibition of transcription factors, which play a role for glioma development and progression such as Ets 1 by specific decoy approaches, might represent useful tools for experimental therapeutic strategies against malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806297

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Anti-miRNA oligonucleotides: A comprehensive guide for design.

Authors:  Joana Filipa Lima; Laura Cerqueira; Ceu Figueiredo; Carla Oliveira; Nuno Filipe Azevedo
Journal:  RNA Biol       Date:  2018-03-23       Impact factor: 4.652

3.  Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes.

Authors:  Christina Durón; Yuan Pan; David H Gutmann; Johanna Hardin; Ami Radunskaya
Journal:  Bull Math Biol       Date:  2018-10-22       Impact factor: 1.758

4.  Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.

Authors:  Christopher H Switzer; Robert Y-S Cheng; Lisa A Ridnour; Sharon A Glynn; Stefan Ambs; David A Wink
Journal:  Breast Cancer Res       Date:  2012-09-12       Impact factor: 6.466

5.  ETS1-activated SNHG10 exerts oncogenic functions in glioma via targeting miR-532-3p/FBXL19 axis.

Authors:  Lide Jin; Shengquan Huang; Congjin Guan; Shun Chang
Journal:  Cancer Cell Int       Date:  2020-12-09       Impact factor: 5.722

6.  microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1.

Authors:  Liduan Zheng; Teng Qi; Dehua Yang; Meng Qi; Dan Li; Xuan Xiang; Kai Huang; Qiangsong Tong
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 7.  Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy.

Authors:  Petra Knizetova; John L Darling; Jiri Bartek
Journal:  J Cell Mol Med       Date:  2007-11-20       Impact factor: 5.310

8.  Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers.

Authors:  Meghan L Verschoor; Chris P Verschoor; Gurmit Singh
Journal:  Cancer Metab       Date:  2013-07-25

9.  Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression.

Authors:  Haiyang Xu; Guifang Zhao; Yu Zhang; Hong Jiang; Weiyao Wang; Donghai Zhao; Hongquan Yu; Ling Qi
Journal:  J Exp Clin Cancer Res       Date:  2019-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.